BIO-TECHNE (TECH) Company Report

Total revenue was $295.9 M, flat year-over-year; adjusted EPS was $0.46, up 10% YoY; adjusted operating margin expanded to 31.1%, +100 bps YoY.
Protein Sciences sales of $215.1 M (+2% reported, –1% organic; +4% ex-cell therapy timing impacts); Diagnostics & Spatial Biology sales of $81.2 M (–4% reported, +3% organic) with segment margin improving to 10.4% from 3.9% YoY.
Geographically, North America revenue declined upper single digits, Europe was flat, China grew mid-single digits for the third consecutive quarter, and APAC ex-China rose almost 20%.
Q3 organic growth is expected to mirror Q2 when excluding cell therapy and OEM timing headwinds, with underlying mid-single-digit growth; full-year operating margin expansion of 100 bps remains on track.
Strategic growth verticals (cell therapy, proteomic instruments, spatial biology, diagnostics) now represent 47% of revenue (vs. 32% in FY2020) with an upper-teens CAGR; M&A remains a priority, including the pending Wilson Wolf acquisition (20% stake, closing by end of 2027).

3 days ago

Transcript

Bio-Techne reports Q2 2026 earnings

TECH

Earnings

Guidance Update

Revenue flat at $295.9 M, with reported and organic growth flat YoY; excluding FDA Fast Track cell therapy timing headwinds, organic growth was 4%.
Adjusted EPS of $0.46 (up 10% YoY) and adjusted operating margin of 31.1% (up 100 bps).
Generated $82.4 M in operating cash flow, invested $5.9 M in capex, ending with $172.9 M cash and a leverage ratio below 1× EBITDA.
Segment highlights: Protein Sciences revenue rose 2% to $215.1 M; Diagnostics & Spatial Biology sales were $81.2 M (–4% reported, +3% organic), with segment margin improving to 10.4%.
Q3 outlook: organic growth expected to be consistent with Q2, with underlying mid-single-digit growth excluding cell therapy and OEM timing headwinds.

3 days ago

Transcript

Bio-Techne announces Q2 FY2026 results

TECH

Earnings

Guidance Update

Bio-Techne reported total Q2 revenue of $295.9 million, flat y/y, with 4% organic growth excluding timing impacts from two large cell therapy customers.
Adjusted operating margin widened 100 bps y/y to 31.1%, driven by productivity and cost management; adjusted EPS increased 10% to $0.46.
Large pharma revenues rose low double digits; emerging biotech declined mid-single digits; U.S. academic end market down low single digits; China sales grew mid-single digits, APAC excluding China up ~20%.
Protein Sciences segment organic sales fell 1% (reported +2%), but grew 4% excluding cell therapy timing; Diagnostics & Spatial Biology segment achieved 3% organic growth after divestiture impacts.
Q3 organic growth is expected to remain in line with Q2, with underlying (ex-cell therapy/OEM headwinds) growth of mid-single digits; full-year operating margin expansion of 100 bps reiterated.

3 days ago

Transcript

Bio-Techne releases Q2 FY2026 results

TECH

Earnings

Revenue was flat year-over-year at $295.9 million in Q2 FY2026.
GAAP EPS of $0.24 rose from $0.22 a year ago; adjusted EPS improved to $0.46 from $0.42.
Adjusted operating margin expanded by 100 bps to 31.1%, while GAAP operating margin increased to 18.4% from 16.0% in Q2 FY2025.
By segment, Protein Sciences net sales grew 2% to $215.1 million, and Diagnostics & Spatial Biology revenue declined 4% to $81.2 million (organic +3%).

3 days ago

8-K

Bio-Techne reports Q2 FY2026 results

TECH

Earnings

Revenue for Q2 FY2026 was $295.9 million, flat year-over-year.
GAAP EPS of $0.24 versus $0.22 prior year; adjusted EPS of $0.46 versus $0.42.
Adjusted operating margin improved to 31.1%, up 100 bps year-over-year.
Protein Sciences revenue increased 2% to $215.1 million; Diagnostics & Spatial Biology revenue decreased 4% to $81.2 million.

3 days ago

Press Release

Bio-Techne outlines 2026 strategy at J.P. Morgan Healthcare Conference

TECH

M&A

Product Launch

Bio-Techne reported $1.2 billion in revenue for 2025, with 81% consumables, 9% instruments, 7% services, and 2% royalties, operating in two segments: protein sciences and diagnostics & spatial biology.
The company targets three high-growth verticals: cell therapies in a $2 billion TAM growing ~20% annually, proteomic applications in a $4 billion addressable market, and spatial biology in a $5 billion market, contributing to a $27 billion total addressable market.
Innovation priorities include AI-designed proteins and the ProPak cytokine delivery system for cell therapy, the Simple Western Leo and ultra-sensitive Ella cartridges for proteomics, and expanded multi-omic capabilities via RNAscope and COMET.
Financially, Bio-Techne has achieved a 10% revenue CAGR over five years, delivered 5% organic growth in fiscal 2025 with 9% operating margin, and targets 35–40% operating margins going forward.
M&A remains strategic: the company holds 20% of Wilson Wolf with plans to acquire the remainder by end of 2027, reinforcing its position in cell therapy bioreactors.

Jan 13, 2026, 5:00 PM

Transcript

Bio-Techne provides strategic overview at 44th J.P. Morgan Healthcare Conference

TECH

Guidance Update

Product Launch

M&A

Bio-Techne reported $1.2 billion in 2025 revenue, driven by 81% consumables with a segment mix of 73% protein sciences and 27% diagnostics & spatial biology. The company delivered a 10% five-year CAGR, 5% organic growth in fiscal 2025, and targets 35–40% operating margins.
The firm addresses a combined $27 billion total addressable market across three growth verticals—discovery, advanced therapeutics manufacturing, and precision diagnostics—and leverages a differentiated portfolio in cell therapies, proteomic analytics, and spatial biology.
Bio-Techne reaffirmed low single-digit revenue growth guidance for fiscal 2026, assuming an “air pocket” due to delayed orders from fast-track cell therapy customers and gradual market recovery.
Upcoming and recent product innovations include AI-designed proteins and ProPak cytokine delivery for cell therapies; the Simple Western Leo and ultra-sensitive Ella immunoassays for proteomic analysis; and enhanced RNAscope proximity assays alongside the COMET multi-omic spatial platform.
The company holds a 20% stake in Wilson Wolf and plans to acquire the remaining interest by end of calendar 2027, integrating the G-Rex disposable bioreactor into its cell therapy solutions.

Jan 13, 2026, 5:00 PM

Transcript

Bio-Techne outlines 2026 strategy at J.P. Morgan Healthcare Conference

TECH

Bio-Techne reported $1.2 billion in 2025 revenue, comprised of 81% consumables, 9% instruments, 7% services and 2% royalties, with 12% of consumables tied to installed instruments.
Revenues split 73% to Protein Sciences and 27% to Diagnostics & Spatial Biology, the latter down slightly after the Exosome Diagnostics divestiture.
The company is targeting three high-growth applications: cell therapies (addressable market of $2 billion, ~20% CAGR) , proteomic analytical instruments ($4 billion TAM) , and spatial biology ($5 billion market).
Over the past five years, Bio-Techne delivered a 10% revenue CAGR and in FY 2025 achieved 5% organic growth with a 9% operating margin, underpinned by productivity and strategic investment.

Jan 13, 2026, 5:00 PM

Transcript

Bio-Techne presents January 2026 corporate strategy and growth

TECH

FY2025 revenue exceeded $1.2 billion, driven by Protein Sciences (73 %) and Diagnostics & Spatial Biology (27 %).
Adjusted operating income reached $384 million in 2025, up from $246 million in 2020.
Company addresses a $27 billion total addressable market, including $14 billion in discovery, $5 billion in advanced therapeutics, and $8 billion in precision diagnostics.
Focused on three strategic growth vectors: cell-based systems & therapies, high-value proteomic applications, and spatial multiomic interrogation.

Jan 13, 2026, 1:00 AM

Presentation

Bio-Techne outlines growth drivers and Fiscal 2026 outlook at Nasdaq Investor Conference

TECH

Guidance Update

Bio-Techne leverages a 50-year core reagents business with four high-growth verticals: cell therapy, proteomics, spatial biology, and molecular diagnostics.
Q1 FY2026 highlights include double-digit growth in large pharma, China back to growth, spatial biology bookings up double digits, and margins of 29.9% versus a 20% forecast, offset by a near-term “air pocket” in cell therapy after two customers received FDA Fast Track approvals.
Biopharma represents 50% of revenue with large pharma (30% of revenue) growing double digits and biotech pressured by mid-teens funding declines but showing improvement; academic research (20% of revenue) faces US budget uncertainty with funding shifting toward neurology, oncology, and weight management.
Full-year FY2026 guidance expects single-digit growth as headwinds in biotech and academic markets persist, with management targeting a return to double-digit growth in a normalized environment and anticipating easier comps in the back half of the year.

Dec 9, 2025, 9:30 AM

Transcript

Earnings Transcripts

Quarterly earnings call transcripts for BIO-TECHNE.

Q2 2026

Feb 4, 2026

→

Q1 2026

Nov 5, 2025

→

Q4 2025

Aug 6, 2025

→

View All Transcripts

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Kim Kelderman say about margins?What are BIO-TECHNE's strategic priorities?How is BIO-TECHNE positioned vs competitors?How did BIO-TECHNE do last quarter?

BIO-TECHNE (TECH)

Analyst Earnings Quarterly Reports

Q1 2026

Q4 2025

Q3 2025

Q2 2025

Q2 2026

Executives

Kim Kelderman

James Hippel

Matthew McManus

Shane Bohnen

William Geist

Board Members

Alpna Seth

Amy Herr

John Higgins

Joseph Keegan

Judith Klimovsky

Julie Bushman

Robert Baumgartner

Rupert Vessey

Analyst Coverage

Puneet Souda

Patrick Donnelly

Dan Arias

Daniel Leonard

Dan Leonard

Matthew Larew

Matt Larew

Sung Ji Nam

Brandon Couillard

Daniel Arias

Daniel Markowitz

Mac Etoch

Brandon Couillard

Catherine Schulte

Conor Noel McNamara

Hannah Hefley

Jacob Johnson

Justin Bowers

Kyle Boucher

Paul Knight

Steven Etoch

Thomas Peterson

Tom DeBourcy

Latest news

Earnings Transcripts

Q2 2026

Q1 2026

Q4 2025

Ask Fintool AI Agent